The FDAs filing Friday was in response to the groups suit, saying its move was effectively the relief that Plaintiffs sought in their motion. In the filing, the agency said that, for the time being, it wouldnt take action against the plaintiffs and their members making compounded versions of the drugs as it re-evaluates its decision
In the SURMOUNT-1 phase-3 trial, tirzepatide produced dose-dependent weight loss reaching about ~21% of total body weight at the 15 mg dose, substantially more than placebo, with gastrointestinal symptoms the most common adverse events [6] [7]
Wegovy, with the active ingredient semaglutide, is a once-weekly GLP-1 medication delivered via a pre-filled injection pen or daily tablet
Professional health assessments ensure safe participation in athletic activities
Scandinavian J Gastroenterol